CN110172083A - Have effects that anti-fat and anti-diabetic peptide and its purposes - Google Patents

Have effects that anti-fat and anti-diabetic peptide and its purposes Download PDF

Info

Publication number
CN110172083A
CN110172083A CN201910508329.1A CN201910508329A CN110172083A CN 110172083 A CN110172083 A CN 110172083A CN 201910508329 A CN201910508329 A CN 201910508329A CN 110172083 A CN110172083 A CN 110172083A
Authority
CN
China
Prior art keywords
peptide
fat
sequence
peptide complex
sequence table
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910508329.1A
Other languages
Chinese (zh)
Other versions
CN110172083B (en
Inventor
郑镕池
金银美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caregen Co Ltd
Original Assignee
Caregen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caregen Co Ltd filed Critical Caregen Co Ltd
Publication of CN110172083A publication Critical patent/CN110172083A/en
Application granted granted Critical
Publication of CN110172083B publication Critical patent/CN110172083B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to the peptide with anti-fat and anti-diabetic and its purposes, peptide and peptide complex of the invention not only inhibits fat accumulation, and the fat accumulated is decomposed anti-fat effect is presented, and effectively reduces blood glucose, to also have the effect of to diabetes outstanding.Peptide of the invention and peptide complex reduce the expression that the peroxisome proliferators activated receptor γ, acetyl-CoA carboxylase and fatty specific fat acid binding protein 2 of factor of character are generated as lipid, and increase the expression that -58 and fat triglyceride lipase are identified as the phosphokinase sensitive lipase, Adenylate cyclase α 1, icp gene of lipolytic factor, and reduce the size and Blood Cholesterol numerical value of fat cell.The outstanding Activity and stabill of peptide and peptide complex of the invention can be effectively applicable to medicine and the outer product of medicine.

Description

Have effects that anti-fat and anti-diabetic peptide and its purposes
The application is the divisional application for the application for a patent for invention of the same name 201580004918.6 submitted on May 12nd, 2015.
[technical field]
The application is set forth in the South Korea patent application 10-2015-0059648 of Koran Office on April 28th, 2015 Number CLAIM OF PRIORITY, the disclosure of above-mentioned application are used as referring to being inserted in this specification.
The present invention relates to the peptide with anti-fat and anti-diabetic and its purposes.
[background technique]
Currently, westernization, the fat mass increase from food absorbed of the South Korea because of economic development and dietetic life, and because of fortune The reasons such as dynamic deficiency, and the metabolic of such as obesity, diabetes, hyperlipemia, hypertension, arteriosclerosis and fatty liver is presented The increased trend of disease.Also, it is fat that negative influence not only is generated to the beautiful facial appearance younger people for liking slender, moreover, Because fat continues, and a variety of diseases can be suffered from.
Currently, the fat therapeutic agent for the treatment of can be broadly divided into act on nervous centralis the medicament that has an impact to appetite and Gastric tube is acted on to hinder the drug absorbed.According to the mechanism of each drug, in the nervous centralis that acts on of market sale Drug is the drugs such as Fenfluramine, the Dexfenfluramine for inhibiting serotonin (5-HT) nervous system, passes through norepinephrine The drugs such as the ephedrine and caffeine of nervous system and it is nearest while act on serotonin and norepinephrine nerveous system It unites to inhibit the drugs such as fat sibutramine.In addition, inhibiting the representative drug of fat drug as stomach/intestinal tube is acted on For as the Ao Lisi top grade for reducing the Bariatric agent authorization of the absorption of fat by inhibiting intestinal tube lipase.But In the drug used in the past, the drugs such as Fenfluramine cause primary pulmonary hypertension or valvulopathy etc. are secondary to make because existing With being thus forbidden to use recently, other drugs can also cause decompression or the problems such as lactic acidosis, thus in the presence of can not be to mental and physical efforts The problem of patients such as failure, kidney trouble use.
Diabetes are that the secretory volume of insulin is insufficient or can not carry out one of metabolic disease caused by normal function etc. Kind (DeFronzo, 1988), it is because of high blood that the feature of diabetes, which is to make the increased hyperglycemia of the concentration of the glucose in blood, Sugar will lead to a variety of symptoms and sign and the disease of glucose is discharged from urine.Recently, because of obesity rates, in particular, because of abdomen fertilizer Fat increase, there are the trend that the incidence of glycosuria sharply increases.
In 2000, the quantity of whole world diabetic was 100,000,000 7 thousand ten thousand, and in the year two thousand thirty, diabetic be will increase To 300,000,000 7 thousand ten thousand, still, according to nearest analysis, pointed out in report, in 2008, whole world diabetic was early had reached 300000000 5 thousand ten thousand (Danaei et al..2011), so that diabetes extension is more serious than expected.It was reported that relative to two type glycosurias For about the 80% of patient the above are obesity, the patient in obese patient less than 10% is diabetic (Harris et al..1987).Above-mentioned diabetes and fat correlation are because of fatty plain (adipokine) and free fatty acid (free fatty Acid episodic secretion), fatty acid are deposited in the insulin-sensitive tissues such as beta cell or kidney, liver, heart, thus Show lipotoxicity (lipotoxicity).It, can be with body if not carrying out treatment appropriate to state of chronic hyperglycemia A variety of symptom, in order to prevent representative property retinopathy, renal failure, neuropathy, because of vascular disorder caused by Complication, effectively Blood sugar management must be carried out by obtaining.
Currently, the method as adjustment blood glucose uses living habit to fix (dietetic treatment, kinesiatrics) and medicinal treatment Deng.But dietetic treatment or kinesiatrics are difficult to carry out stringent management and implementation, and there is also limitations for its effect.Therefore, greatly Part diabetic correct living habit, and dependent on insulin, insulin secretion stimulators, insulin sensitivity improver and The blood glucose adjustment effect of the drugs such as Hypoylycemic agents.
The insulin produced by recombination method to a diabetes mellitus type and can not adjust blood glucose two type patients it is necessary Drug, said medicine is conducive to adjust blood glucose, but exist it is dangerous to the dislike, the difficulty of medication, hypoglycemia of needle and The disadvantages of weight gain.
The preparation that a kind of meglitinides as insulin secretion stimulators are exceedingly fast as drug effect, bfore meals, Insulin secretion stimulators have NovoNorm (Repaglinide), Fastic (Nateglinide), Glufast (Mitiglinide) etc..But When individually taking insulin sensitivity improver, it is characterized in that, almost without hypoglycemia, insulin sensitivity improver has work For the metformin (metformin) and thiazolidinedione of biguanides (biguanide) class drug (thiazolidinedione) Avaneda (rosiglitazone), Actoc (pioglitazone) of class.
It is favorably used as promoting insulin secretion and hormone glucagon-like-peptide-1 as the drug developed recently Glucagon-like-peptide-1 (GLP-1) agonist for acting on developing of (Glucagon-like peptide-1) (agonist), glucagon-like-peptide-1 agonist is antidiabetic drug (exenatide) and Liraglutide (liraglutide).And And inhibit as dipeptidyl peptidase-4 (DPP-4, the Dipeptidyl for making the inert enzyme of glucagon-like-peptide-1 Peptidase-4 the dipeptidyl peptidase-4 inhibitors (Inhibitor) of effect) are also in the new drug developed recently, and representative Product is Januvia (ingredient name: sitagliptin (sitagliptin)).But above-mentioned medicament have hepatotoxicity wind agitation, gastrointestinal disorders, The side effects such as cardiovascular disease and carcinogenicity, and annual medical expense is also high, to be difficult through above-mentioned dipeptidyl peptidase- 4 inhibitor for treating diabetes.In fact, prediabetes (pre-diabetes) and diabetes are related on the basis of 2007 Expense is only in the U.S. just close to about 200 hundreds of millions yuan (Dall et al., 2010), and on the basis of 2008, fat correlative charges is only In the U.S. also close to 150 hundreds of millions yuan (Finkelstein et al., 2009).It can be by reducing weight simultaneously therefore, it is necessary to develop Blood glucose is effectively reduced while treating the medicament of diabetes and fat diabetes and few side effects.
Firstly, focusing on adjustment energetic supersession recently to find out for treating the fat method further improved Method, under the premise of the compound of this side's sequence must have more high stability (hypotoxicity), when people absorb high fat diet When, to the signal for being piled into fat and the protein that fat accumulation has an impact is studied, inhibits above-mentioned fat accumulation Protein expression, promoted by signal research for decomposing the fat accumulated and GAP-associated protein GAP Quality Research Into lipolysis research and develop peptide.Also, peptide of the invention generates the diabetes because of caused by diabetes and obesity Brilliant effect.The fat accumulation that causes due to high fat diet inhibits to present because of the fat accumulation of liver or muscle etc. The signal of insulin, the insulin thus caused patience become the reason of causing diabetes, each peptide of the invention and compound Body tells on to above-mentioned diabetes and fat diabetes treatment.
In this specification, more papers and patent document are had references to, and illustrate its reference.Cited paper and The disclosure of patent document is entirely insertable in this specification as reference, to definitely illustrate technology belonging to the present invention The level and the contents of the present invention in field.
[summary of the invention]
[solving the problems, such as]
The present inventor makes great efforts exploitation with biologically effective active multiple outstanding peptides as a result, having found out with sequence The sequence 1 of list to sequence table sequence 7 amino acid sequence peptide inhibit because of caused by high fat diet fat accumulation, point The fat that solution has been accumulated is presented anti-fat effect, moreover, also having to diabetes, fat diabetes or diabetic complication Outstanding effect, has thus completed the present invention.
Therefore, amino documented by the sequence 7 that the object of the present invention is to provide the sequences 1 as sequence table to sequence table The peptide that acid sequence is formed.
It is a further object of the present invention to provide with anti-fat or anti-diabetic activity peptide.
Another object of the present invention is to provide with anti-fat or anti-diabetic activity peptide complex.
A further purpose of the present invention is to provide fat prevention or treatment medicament composition.
It is a further object of the present invention to provide the prevention of glycosuria or treatment medicament compositions.
Other objects of the present invention and advantage by following detailed description of the invention, it is above invent claimed range and with Lower attached drawing becomes more clear.
[solution to problem]
According to an embodiment of the present invention, the present invention is provided by the sequence 7 selected from the sequence 1 by sequence table to sequence table In documented amino acid sequence composition the peptide that is formed of one of group amino acid sequence.
A further embodiment according to the present invention, the present invention are provided by the sequence selected from the sequence 1 by sequence table to sequence table The peptide with anti-obesity or anti-diabetic activity that one of the group of amino acid sequence composition of column 7 amino acid sequence is formed.
A further embodiment according to the present invention, the present invention, which provides, has anti-fat or anti-diabetic activity peptide compound Body, it is above-mentioned to include with anti-fat or anti-diabetic activity peptide complex: (a) peptide formed by the sequence of sequence table 1；(b) The peptide formed by the sequence 2 of sequence table or the sequence 3 of sequence table: and (c) by the sequence of sequence table 6 or the sequence of sequence table 7 The peptide of formation.
The present inventor makes great efforts multiple outstanding peptides that exploitation has biology effective active, as a result, has found out with sequence table Sequence 1 to sequence table sequence 7 amino acid sequence peptide inhibit because of caused by high fat diet fat accumulation, decompose Anti- fat effect is presented in the fat of accumulation, moreover, also have to diabetes, fat diabetes or diabetic complication outstanding Effect.
In the present specification, term " peptide " refers to through peptide bond be combined with each other as more amino acid made of it is linear Molecule.Peptide of the invention can be by chemical synthesis process as known in the art, for example, solid phase synthesis technique (solid-phase synthesis techniques:Merrifield,J.Amer.Chem.Soc.85:2149-54(1963)；Stewart,et al.,Solid Phase Peptide Synthesis,2nd.ed.,Pierce Chem.Co.:Rockford,111(1984)) Or liquid phase synthesis techniques (U.S. log in patent the 5th, 516,891) are prepared.
It a part of position of peptide selection amino acid sequence of the invention simultaneously can be in the end N- or C- in order to increase its activity End induced distortion.By above-mentioned deformation, peptide of the invention can have the higher of half-life period when improving to people's vivo medicine-feeding Half-life period.
An example according to the present invention, the end N- or the end C- of peptide can be deformed into hydroxyl (- OH), amino (- NH2), fold Nitride (- NHNH2) etc..Preferred embodiment in accordance with the present invention, the end N- of above-mentioned peptide are combined with protecting group, above-mentioned protecting group Selected from comprising acetyl group, fluorenylmethyloxycarbonyl, formoxyl, palmityl, myristyl, stearyl and polyethylene glycol (PEG, Polyethylene glycol) group.
The deformation of above-mentioned amino acid plays the role of substantially improving the stability of peptide of the invention.It refers in the present invention Term " stability " refers not only to " internal " stability, also refers to storage stability (for example, normal temperature storage stability).Above-mentioned protection Base plays the role of the peptide of the invention from the attack protection of the intracorporal protein nickase of biology.
An example according to the present invention, peptide of the invention show inhibition fat accumulation because of caused by high fat diet, And the effect for the fat accumulated is decomposed, reduce the peroxisome proliferation-activated receptors that factor of character is generated as lipid The expression of γ (PPAR γ), acetyl-CoA carboxylase (ACC) and fatty specific fat acid binding protein (aP2), and increase work For lipolytic factor phosphokinase sensitive lipase (pHSL), Adenylate cyclase α 1 (AMPK- α 1), compare The expression of identified for genes -58 (CGI-58) and fat triglyceride lipase (ATGL), and reduce the size and blood of fat cell Middle cholesterol numerical value.Also, peptide of the invention effectively reduces blood glucose.The above results mean peptide of the invention to fat, glycosuria Disease and fat diabetes treatment have extremely outstanding effect.
In peptide of the invention, it is not only to indicate with the amino acid sequence of the sequence 7 of the sequence 1 of sequence table to sequence table Each peptide shows outstanding anti-fat and anti-diabetic activity, and these complex also show it is outstanding anti-fat and Anti-diabetic activity.
According to the present invention, it is respectively by the peptide that the sequence 7 of the sequence of sequence table 3, the sequence of sequence table 5 and sequence table is formed The peptide of Ser is replaced as by the Cys of the peptide formed with the sequence 2 of sequence table, the sequence of sequence table 4 and the sequence 6 of sequence table, on The anti-fat and anti-diabetic activity for stating two peptides is almost the same.
An example according to the present invention, of the invention has anti-fat or anti-diabetic activity peptide complex by the group of peptide It closes and is formed, above-mentioned peptide combination includes the peptide formed by the sequence 1 of sequence table, by the sequence 2 of sequence table or 3 shape of sequence of sequence table At peptide and the peptide that is formed by the sequence 6 of sequence table or the sequence 7 of sequence table.
Another example according to the present invention, peptide complex of the invention by the sequence 1 of sequence table, the sequence of sequence table 3 and The combination of the sequence 7 of sequence table is formed.
Another embodiment according to the present invention, it includes the obesity of peptide or peptide complex as effective component that the present invention, which provides, Prevention or treatment medicament composition.
Peptide of the invention or peptide Complex Inhibition fat generate, and the function of decomposing lipid is brilliant, therefore can be used for obesity Prevention or treatment.
Another embodiment according to the present invention, it includes the glycosuria of peptide or peptide complex as effective component that the present invention, which provides, Prevention or treatment medicament composition.
Peptide or peptide complex of the invention shows the effect of increased blood glucose is effectively reduced in diabetes animal model, So as to the prevention or treatment for glycosuria.
Preferred embodiment in accordance with the present invention, composition of the invention are the peptide or peptide complex of (a) aforementioned present invention Pharmacy effective dose；And (b) include the carrier received in pharmacy medicament composition.
The term " pharmacy effective quantity " used in the present specification refer to reach it is related with above-mentioned interleukin 3 Peptide the effect of or active substantial amount.
The load usually utilized when being contained in the carrier received in the pharmacy of pharmaceutical composition of the invention as preparation Body includes lactose, glucose, sucrose, D-sorbite, mannitol, starch, Arabic gum, calcium phosphate, alginates, gelatin, silicon Sour calcium, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, hydroxyl Propyl benzoate, talcum, magnesium stearate and mineral oil etc., but not limited to this.Pharmaceutical composition of the invention is in addition to above-mentioned It also may include lubricant, wetting agent, sweetener, flavoring agent, emulsifier, suspending agent, antistaling agent etc. except ingredient.Medicine appropriate The carrier and preparation received in agent be recorded in detail Remington ' Pharmaceutical Sciences (19th ed., 1995)。
Pharmaceutical composition of the invention can carry out oral medication or non-oral administration, also, in the feelings of non-oral administration It, can be by intravenous injection, subcutaneous injection, intramuscular injection, oral cavity injection, local application, transdermal administration etc. come medication under condition.
The appropriate dosage of pharmaceutical composition of the invention can according to preparation ways, application method, patient age, Weight, gender, the patient's condition, food, administration time, medication path, drainage rate and reaction irritability are located to give in many ways Side.On the other hand, the preferred dosage of pharmaceutical composition of the invention is daily 0.0001-1000 μ g.
The composition of pharmacy of the invention is that person of an ordinary skill in the technical field is easy to implement according to the present invention Method, carried out using the carrier and/or excipient allowed in pharmacy it is formulation, thus be prepared into unit capacity form or It is put into large-rolume container and is prepared.At this point, dosage form can be solution, suspension or the cream in oil or aqueous medium Agent form is either also possible to extract, powder agent, granule, tablet, capsule or glue (for example, hydrogel) form, It and can additionally include dispersing agent or stabilizer.
[The effect of invention]
It is as follows to summarize conclusion feature and advantage of the invention:
(i) peptide of the invention and peptide Complex Inhibition fat accumulation, and decompose the fat accumulated and imitated anti-obesity is presented Fruit, moreover, blood glucose is effectively reduced, so that diabetes are presented with outstanding effect.
(II) peptide of the invention and peptide complex reduce the peroxisome proliferation that factor of character is generated as lipid The expression of activated receptor γ, acetyl-CoA carboxylase and fatty specific fat acid binding protein, and increase as lipolysis Phosphokinase sensitive lipase, Adenylate cyclase α 1, icp gene identification -58 and the fat triglyceride of the factor The expression of lipase, and reduce the size and Blood Cholesterol numerical value of fat cell.
The outstanding Activity and stabill of (III) peptide of the invention and peptide complex can be effectively applicable to medicine and the outer product of medicine.
[Detailed description of the invention]
Fig. 1 a, Fig. 1 b and Fig. 1 c are to be confirmed by oil red O (Oil red O) dyeing when handling peptide of the invention The result of the fat of accumulation.The peptide of the sequence 1 of (Fig. 1 a) sequence table, the peptide of the sequence 3 of (Fig. 1 b) sequence table, (Fig. 1 c) (sequence The peptide of the sequence 5 of table).
Fig. 2 is to pass through oil red to confirm the fat accumulated when handling by concentration peptide complex of the invention The result of O dyeing confirmation.
Fig. 3 a, Fig. 3 b and Fig. 3 c are to be measured when handling peptide of the invention as the lipogenetic gene of participation The result of the expression quantity of fatty specific fat acid binding protein 2.1 peptide of sequence of (Fig. 3 a) sequence table, (Fig. 3 b) sequence table The peptide of sequence 3, (Fig. 3 c), the peptide of the sequence 5 of sequence table.
Fig. 4 is when handling by concentration peptide complex of the invention, and when synthesizing lipid, measurement is used as important base Peroxisome proliferators activated receptor γ, acetyl-CoA carboxylase, fatty 2 base of specific fat acid binding protein of cause The result of the expression quantity of cause.
Fig. 5 is when handling by concentration peptide complex of the invention, and when synthesizing lipid, measurement is used as important egg The peroxisome proliferators activated receptor γ of white matter, phosphokinase sensitive lipase (phospho-HSL) protein The result of expression quantity.
Fig. 6 a, Fig. 6 b, Fig. 6 c and Fig. 6 d are that measurement participates in decomposing when handling peptide of the invention and peptide complex The expression quantity of the Adenylate cyclase α 1 and more firm gene -58 as gene of the process for the fat accumulated As a result.The peptide of the sequence 1 of (Fig. 6 a) sequence table, the peptide of the sequence 3 of (Fig. 6 b) sequence table, the peptide of the sequence 5 of (Fig. 6 c) sequence table, (Fig. 6 d) is compound by the peptide that the amino acid sequence of the sequence 1 of sequence table, the sequence of sequence table 3 and the sequence 7 of sequence table indicates Body.
Fig. 7 is measurement when handling by concentration peptide complex of the invention, accumulates fat as participating in decomposing Process protein fat triglyceride lipase expression quantity result.
Fig. 8 a, Fig. 8 b, Fig. 8 c and Fig. 8 d are to be measured using immunostaining when handling peptide of the invention, utilize work By participate in decompose accumulation fat process protein phosphokinase sensitive lipase expression quantity result.(Fig. 8 a) The peptide of the sequence 1 of sequence table, the peptide of the sequence 3 of (Fig. 8 b) sequence table, the peptide of the sequence 5 of (Fig. 8 c) sequence table, (Fig. 8 d) passes through The peptide complex of the amino acid sequence expression of the sequence 1, the sequence of sequence table 3 and the sequence 7 of sequence table of sequence table.
Fig. 9 is the result of measurement production quantity of glycerol when handling by concentration peptide complex of the invention.
Figure 10 a is measurement in obesity mice experimental model, institute after handling by concentration peptide complex of the invention The result of the adipose tissue of decomposition.Figure 10 b is to handle in measurement obesity mice experimental model peptide complex of the invention The size of the adipose tissue decomposed afterwards and the result of numerical value.
Figure 11 is to decompose institute's heap as participation using immunostaining measurement when handling peptide complex of the invention The result of the expression quantity of the phosphokinase sensitive lipase of the protein of the process of adipopexia fat.
Figure 12 is the variation (a) and examination of measurement weight in obesity mice when handling peptide complex of the invention The result of material intake variation (b).
Figure 13 is the result of measurement shape of obesity mice when handling peptide complex of the invention.
Figure 14 is that the C57BL/6 mouse model as experimental animal model is made to absorb greasy feed to make obesity mice mould Type, and after handling peptide complex of the invention, pass through microcomputer layer scanning technology shooting measurement Fat Distribution As a result.
Figure 15 is that the C57BL/6 mouse model as experimental animal model is made to absorb greasy feed to make obesity mice mould Type, and after handling peptide complex of the invention, the result for acquiring adipose tissue to observe.
Figure 16 a is that the C57BL/6 mouse model as experimental animal model is made to absorb greasy feed to make obesity mice Model, and after handling peptide complex of the invention, adipose tissue is acquired to observe the knot of fat cell shape Fruit.Figure 16 b is that the C57BL/6 mouse model as experimental animal model is made to absorb greasy sample to form Mice model of obesity, And after handling peptide complex of the invention, adipose tissue is acquired to observe the result of fat cell size.
Figure 17 is that the C57BL/6 mouse model as experimental animal model is made to absorb greasy feed to make obesity mice mould Type, and after handling peptide complex of the invention acquires adipose tissue to observe as acting on fat cell The result of the expression quantity of the phosphokinase sensitive lipase of the protein of interior lipolysis.
Figure 18 is that the C57BL/6 mouse model as experimental animal model is made to absorb greasy feed to make obesity mice mould Type, and after handling peptide complex of the invention, blood is acquired to measure the result of cholesterol amount.
Figure 19 is that the C57BL/6 mouse model as experimental animal model is made to absorb greasy feed to make obesity mice mould Type, and after handling peptide complex of the invention, blood is taken to measure the result of blood glucose.
Figure 20 a, Figure 20 b are to handle in the DBDB mouse model of induced Diabetic peptide complex of the invention Later, blood is acquired to measure the result of the variation of blood glucose.
Figure 21 is after handling peptide complex of the invention, to adopt in the DBDB mouse model of induced Diabetic Collect blood to measure the result of the variation of cholesterol.
Figure 22 a, Figure 22 b, Figure 22 c be cause diabetes DBDB mouse model in, to peptide complex of the invention into After row processing, blood is acquired to measure the result of the variation of blood glucose.The peptide of the sequence 1 of (Figure 22 a) sequence table, (Figure 22 b) sequence The peptide of the sequence 3 of list, the peptide of the sequence 5 of (Figure 22 c) sequence table.
Figure 23 is to measure type-1 insulin like growth factor when the peptide of the sequence 7 to sequence table of the invention is handled (IGF-1) and the result of the expression quantity of insulin.
Figure 24 is in the DBDB mouse model of induced Diabetic, at the peptide of the sequence 7 of sequence table of the invention After reason, blood is acquired to measure the result of the variation of blood glucose.
Figure 25 a, Figure 25 b, Figure 25 c, Figure 25 d be in the high diabetic of blood glucose, to peptide complex of the invention into After row processing, blood is acquired to measure the result of the variation of blood glucose.
[specific embodiment]
Hereinafter, the present invention is described in more detail by embodiment.These embodiments are only used for more specifically Illustrate that the present invention, the scope of the present invention are limited to these embodiments not according to the gist of the invention, this is for the present invention It is obvious for person of an ordinary skill in the technical field.
[embodiment]
[synthesis example 1: peptide synthesis]
By chlorine trityl chloride resin (the Chloro trityl chloride resin of 700mg；CTL resin, Nova Biochem Cat No.01-64-0021) it is put into reaction vessel, and add METHYLENE CHLORIDE (MC, the methylene of 10ml Chloride it) stirs 3 minutes.Solution is removed, and is put into dimethylformamide (DMF, the Dimethyl of 10ml Formamide it) stirs 3 minutes and then secondary removing solvent.To reactor be put into 10ml methylene chloride (DCM, Dichloromethane) solution, and it is put into fluorenylmethyloxycarbonyl-Fmoc-Asn (Trt)-OH of 200mmole) (Ba Heng company (Bachem), Switzerland (Swiss)) and 400mmole n,N-diisopropylethylamine (DIEA, N, N- Diisopropylethylamine being stirred after) makes their uniform dissolutions, is stirred for 1 hour and is reacted.After reaction It is cleaned, methanol and DIEA (2:1) is dissolved in DCM and react within 10 minutes, and is carried out with excessive DCM/DMF (1:1) Cleaning.Solution is removed, and the DMF for being put into 10ml stirs 3 minutes and then secondary removing solvent.By the deprotection solution of 10ml (20% piperidines (Piperidine)/DMF) is put into reaction vessel, removes solution after stirring 10 minutes at normal temperature.It is put into Same amount of deprotection solution, then maintain to remove solution after reaction in 10 minutes, and cleaned 2 times every 3 minutes with DMF respectively, It is cleaned 1 time with MC, and is cleaned 1 time with DMF, to be prepared for Arg (pbf)-chlorine trityl chloride resin (Asn-CTL Resin). It is put into the DMF solution of 10ml to new reactor, and is put into fluorenylmethyloxycarbonyl-γ-trityl-L- glutamy of 200mmole Amine (Fmoc-Arg (Pbf)-OH) (Bachem, Swiss), the hydroxybenzotriazole (HoBt) of 200mmole and the benzene of 200mmole And it is stirred after three (dimethylamino) phosphorus hexafluorophosphate (Bop) of triazole -1- base oxygroup to keep them uniformly molten Solution.It is put into n,N-diisopropylethylamine (DIEA, N, the N- of 400mmole in two times to reactor in a manner of fractionation Diisopropylethylamine it) after 2 times, minimally stirs 5 minutes, until all solids dissolution.It will dissolution Amino acid mixed solution be put into deprotection resin reaction vessel, and stir 1 hour and reacted at normal temperature.It removes Dereaction liquid is removed after stirring 3 in 5 minutes is taken second place with DMF solution.A small amount of reacting resin is taken out, and utilizes ninhydrin It tests (Nihydrin test) and checks the extent of reaction.Same as mentioned abovely, 2 deprotections are carried out instead with deprotection solution It answers, to be prepared for Arg-Asn-CTL resin.It is sufficiently cleaned with DMF and MC, it is and upper after executing a ninhydrin test again It states method in the same manner, performs amino acid attachment experiment below.By selected amino acid sequence, with Fmoc-Tyr (tBu)- OH, Fmoc-Lys (Boc)-OH and Fmoc-Leu-OH sequence have carried out chain reaction.Make Fmoc- protecting group with deprotection solution After reaction in 10 minutes 2 times, removed by uniformly cleaning.It is put into acetic anhydride and DIEA, hydroxybenzotriazole After (HoBt, Hydroxybenzotriazole) executes acetylation in 1 hour, with DMF, MC and methanol respectively by manufactured peptidyl Resin cleans 3 times, slowly flows out nitrogen air after being dried, in phosphorus pentoxide (P2O5, Phosphorus Pentoxide it is depressurized, is waited after being completely dried with vacuum under the conditions of), be put into the leakage solution [trifluoroacetic acid of 30ml (TFA, Trifluroacetic acid) 81.5%, distilled water 5%, thioanisole (Thioanisole) 5%, phenol (Phenol) 5%, EDT 2.5% and TIS 1%] after, it rocks once in a while at normal temperature, and maintain react for 2 hours.To resin into Row filtering, and with a small amount of solution clean resin later by it with mother liquor altogether.It is distilled using decompression, so that overall volume Surplus half or so, and after adding the cool ether induced precipitation of 50ml is centrifuged to collect precipitating, and with cooler ether Cleaning 2 times.Mother liquor is removed, and sufficiently dry under the conditions of nitrogen, the NH of 0.85g has been synthesized before purification2-Leu-Lys-Thr- (the yield: 92%) of Arg-Asn-COOH peptide 1.The NH of 0.78g has been synthesized by sequence 2 and sequence 32-Lys-Gly-Ala-Cys (Ser) (yield: 82%), sequence 4 and sequence 5 have synthesized the NH of 0.92g to-Thr-Gly-Trp-Met-Ala-COOH2-Ala- Cys (Ser) Thr-Leu-Pro-His-Pro-Trp-Phe-Cys (Ser)-COOH (yield: 85%).It is closed by sequence 6 and sequence 7 At the NH of 0.76g2- Cys (Ser)-Asp-Leu-Arg-Arg-Leu-Glu-Met-Tyr-Cys (Ser)-COOH (yield: 88%).When being measured using molecular weight estimation apparatus, the molecular weight of the peptide of sequence 1 be 630.7 (theoretical value: 630.7), sequence 2 Molecular weight be 924.5 (theoretical value: 924.1), the molecular weight of sequence 4 be 1263 (theoretical value: 1236.5), point of 6 peptide of sequence Son amount is 1301.5 (theoretical values 1301.5).
[table 1]
On the other hand, the sequence 1 of same amount of sequence table, the peptide of the sequence of sequence table 3 and the sequence 7 of sequence table are mixed Peptide complex is formed, and the effect of complex is evaluated.
[embodiment 1: evaluation lipid generates inhibitory activity]
[1-1. inhibits (oil red O stain (Oil red O staining)) using the lipid accumulation of PECTORAL LIMB SKELETON]
By as the 3T3-L1 cell culture of PECTORAL LIMB SKELETON (pre-adipocyte) to converging (Confluent) state Later, it is exchanged into comprising 10 μ g/ml insulin, 0.1 μM of dexamethasone and 0.5 μM of 1- methyl -3- isobutyl group xanthine (IBMX) differential medium and peptide is handled by concentration and is cultivated 2 days, had exchanged at every 2 days later comprising 10 μ g/ The culture medium of ml insulin implements oil red O dye after induction 10 days in order to confirm intracellular droplets (droplet) Color.It is solid using 3.7% formalin after the 3T3-L1 PECTORAL LIMB SKELETON prepared by phosphate buffer (PBS) cleaning It is 1 hour fixed, after being washed using 60% isopropanol, oil red O solution is handled and has dyed 20 points at room temperature Clock.After dyeing, oil red O solution is removed, after carrying out washing three times with distilled water, is observed and is colored using phase contrast microscope Cell.Also, in order to which quantitative analysis moves 200 μ l to 96 orifice plates after 100% isopropyl alcohol extracting fat every time, And absorbance is determined in 500nm by enzyme-linked immunosorbent assay instrument.
Experimental result can be by dyeing oil red O when the peptide to the sequence 1 of sequence table, sequence 3 and sequence 5 is handled Confirm the reduction (Fig. 1 a- Fig. 1 c) of intracellular fat accumulation degree.
Also, when being handled by peptide complex of the concentration to the sequence 1 of sequence table, sequence 3 and sequence 7, it may be determined that The reduction (Fig. 2) of intracellular fat accumulation degree.
[expression inhibiting that 1-2. participates in the gene that lipid generates]
By 3 × 105The cell density of cells/well has planted 3T3-L1 (PECTORAL LIMB SKELETON) in 6 orifice plates.Culture 24 hours Later, peptide is handled by concentration (0.1,1,10 μ g/ml), and has been cultivated in 37 DEG C of culture medium 14 days.It is tied in recycling After the cell of beam culture, ribonucleic acid (RNA) is extracted solution (Easy Blue, introne (Intron)) and is handled After preparing ribonucleic acid, complementary DNA (cDNA) (cDNA) has been synthesized using RT premix (introne).Using for Each factor of character (peroxisome proliferators activated receptor γ, acetyl-CoA carboxylase, fatty specific fat acid knot Hop protein 2) primer and polymerase chain reaction (PCR) premix (introne) carried out polymerase chain reaction.
Target-the specific primer sequence for generating index factor polymerase chain reaction for lipid is as follows: peroxidase Body proliferator activated receptor γ forward primer sequence, 5 '-TTTTCAAGGGTGCCAGTTTC-3 ' and peroxisome proliferation The reverse primer of activated receptor γ, 5 '-AATCCTTGGCCCTCTGAGAT-3 ' (annealing temperature, 60 DEG C)；Acetyl-CoA carboxylase Forward primer sequence, 5 '-ACCTTACTGCCATCCCATGTGCTA-3 ' and the reverse primer of ACC, 5 '- GTGCCTGATGATCGCACGAACAAA-3 ' (annealing temperature, 60 DEG C)；Fatty 2 forward primer of specific fat acid binding protein Sequence, 5 '-CATCAGCGTAAATGGGGATT-3 ' and the reverse primer of fatty specific fat acid binding protein 2,5 '- ACACATTCCACCACCAGCTT-3 ' (annealing temperature, 60 DEG C).
To 1% Ago-Gel load the polymerase chain reaction product of 5 μ l every time and carry out electrophoresis after, in Gel- It confirmed band in Doc.
In Mouse Bone cell strain 3T3-L1, the peptide of the sequence 1 of sequence table, sequence 3 or sequence 5 is handled and cultivated 3 days, as a result, observable reduces (figure as the expression for the fatty specific fat acid binding protein 2 that lipid generates factor of character 3a- Fig. 3 c).
In Mouse Bone cell strain 3T3-L1, with the concentration of 0.1 μ g/ml, 1 μ g/ml and 10 μ g/ml to the sequence of sequence table 1, the peptide complex of the sequence 7 of the sequence 3 and sequence table of sequence table is handled and is cultivated 3 days, as a result, observable is as lipid Generate the peroxisome proliferators activated receptor γ, acetyl-CoA carboxylase, fatty specific fat acid knot of factor of character The expression of hop protein 2 is in tumor necrosis factor-alpha (TNF α) the processing group and peptide complex as positive controls 100ng/ml (Fig. 4) is reduced in processing group.
[1-3. generates and decomposes inducible protein matter expression observation using the lipid of PECTORAL LIMB SKELETON]
By 3 × 105The cell density of cells/well has planted 3T3-L1 (PECTORAL LIMB SKELETON) in 6 orifice plates.Culture 24 hours Later, peptide complex is handled by concentration (0.1 μ g/ml, 1 μ g/ml and 10 μ g/ml), and is cultivated in 37 DEG C of culture mediums 14 days.After ensuring dissolved matter by processing Cell lysis buffer, quantifying for protein is carried out, using as fat life At the antiperoxidase body proliferator activated receptor gamma antibodies (Santa Cruz Biotechnology, USA) and work of the factor It is carried out for the anti-phosphokinase sensitive lipase antibody (Santa Cruz Biotechnology, USA) of lipolytic factor Immunoblotting assay.
When concentration pair is pressed in the expression for the peroxisome proliferators activated receptor γ protein for generating label as fat When peptide complex is handled, observable peptide complex with concentration dependent is reduced, when observation is marked as lipolysis Phosphokinase sensitive lipase protein expression quantity when, in peptide complex processing group, peptide complex increases observable Add (Fig. 5).
[embodiment 2: lipolytic activity evaluation]
[expression that 2-1. participates in the gene of lipolytic increases]
By 3 × 105The cell density of cells/well has planted 3T3-L1 (PECTORAL LIMB SKELETON) in 6 orifice plates.Culture 24 hours Later, peptide is handled by concentration (0.1 μ g/ml, 1 μ g/ml and 10 μ g/ml), and has been cultivated 14 days in 37 DEG C of culture mediums (positive controls: 100ng/ml tumor necrosis factor-alpha (Sigma Corporation (SIGMA))).Recycling culture complete cell it Afterwards, it solution (Easy Blue, Intron) is extracted to ribonucleic acid is handled and after preparing ribonucleic acid, premixed using RT It closes liquid (Intron) and has synthesized complementary DNA (cDNA) (cDNA).Using for each factor of character (adenylate activated protein Kinases α 1, more firm gene -58) primer and polymerase chain reaction premix (Intron) Lai Jinhang polymerase chain it is anti- It answers.
Target-the specific primer sequence for generating factor of character polymerase chain reaction for lipid is as follows: adenosine acid activation egg White 1 forward primer sequence of kinases α, 5 '-TGACCGGACATAAAGTGGCTGTGA-3 ' and Adenylate cyclase α 1 are reverse Primer, 5 '-TGATGATGTGAGGGTGCCTGAACA-3 ' (annealing temperature, 60 DEG C)；More firm -58 forward primer sequence of gene Column, 5 '-TGTGCAGGACTCTTACTTGGCAGT-3 ' and the reverse primer of more firm gene -58,5 ' - GTTTCTTTGGGCAGACCGGTTTCT-3 ' (annealing temperature, 60 DEG C).
After loading the polymerase chain reaction product of 5 μ l every time to 1% Ago-Gel and carry out electrophoresis, in Gel-Doc In confirmed band.
In PECTORAL LIMB SKELETON (3T3-L1), peptide is handled and is cultivated, as a result, observable is marked as lipolytic Adenylate cyclase α 1 and icp gene identification -58 expression in each peptide processing group increase (Fig. 6 a~figure 6c).Also, in the case where handling peptide complex, Adenylate cyclase α 1 and icp gene mirror can be confirmed Fixed -58 expression is increased in a manner of relying on concentration, when the tumor necrosis factor-alpha with the 100ng/ml as positive controls When processing group is compared, the expression of observable lipolytic factor sharply increases (Fig. 6 d).
[2-2. expresses observation using the lipolytic inducible protein matter of PECTORAL LIMB SKELETON]
By 3 × 105The cell density of cells/well has planted 3T3-L1 (PECTORAL LIMB SKELETON) in 6 orifice plates.Culture 24 hours Later, peptide is handled by concentration (0.1 μ g/ml, 1 μ g/ml and 10 μ g/ml), and has been cultivated 14 days in 37 DEG C of culture mediums (positive controls: the tumor necrosis factor-alpha (Sigma Corporation) of 100ng/ml).Cell lysis buffer is handled to come After ensuring dissolved matter, protein is quantified, using as the anti-cellulite triglyceride lipase antibody of lipolytic factor Carry out immunoblotting assay.
It can confirm that the expression of the fat triglyceride lipase as lipolytic factor increases (Fig. 7) by peptide complex.
[2-3. expresses fluorescence microscope using the lipolytic inducible protein matter of PECTORAL LIMB SKELETON]
By 3 × 105The cell density of cells/well has planted 3T3-L1 (PECTORAL LIMB SKELETON) in 6 orifice plates.Culture 24 hours Later, peptide or peptide complex (1 μ g/ml) are handled, and cultivated in 37 DEG C of culture mediums 14 days (positive controls: The tumor necrosis factor-alpha (Sigma Corporation) of 100ng/ml).After the fixed cell for terminating culture of 70% ethyl alcohol, utilize Anti- phosphokinase sensitive lipase antibody (Santa Cruz Biotechnology, USA), is seen by cellular immunity decoration method Examine the cell inner expression of the phosphokinase sensitive lipase as lipolysis inducible factor.
Experimental result can be identified through each peptide (Fig. 8 a~Fig. 8 c) and peptide complex (Fig. 8 d), lure as lipolysis The expression of the phosphokinase sensitive lipase of inducement will increase.
[2-4. is fixed as the measurement of the glycerol of lipidtemns]
After the abdomen of fat inducing mouse acquisition adipose tissue, in 24 well culture plates, 100mg is put into each hole Adipose tissue after, culture medium (the Krebs-Ringer buffer (buffer) of 1ml include 25mM 4- hydroxyethyl piperazine Ethanesulfonic acid (HEPES), the glucose (glucose) of 5.5mM and 2% (w/v) bovine serum albumin(BSA) (bovine serum Albumin it is cultivated in)).When culture when, with the concentration of 0.1 μ g/ml, 1 μ g/ml and 10 μ g/ml to complex at Reason has handled the tumor necrosis factor-alpha of 100ng/ml and has determined after culture 48 hours from fat as positive controls The amount of the glycerol decomposited.
Experimental result, when handling by concentration peptide complex, observable fat is in lipolysis during institute The amount of the glycerol of generation increases in a manner of dependent on peptide complex concentration for the treatment of.It confirmed and the tumour as positive controls Necrosis factor-alpha processing group is compared, and detects further amounts of glycerol (Fig. 9).
[2-5. confirms the discomposing effect of obesity mice isolated adipose tissue]
According to color, adipose tissue is divided into white adipose (White Fat), brown fat (Brown Fat), according to portion Position, adipose tissue are divided into film fat (interior fat) and epididymal adipose tissues between subcutaneous fat, stomach fat, intestines.After dissection, pluck Fat and after separating white adipose unless each, with the weight in each hole 100mg/, in 24 orifice plates, at complexing agent concentration After reason, in culture medium, (the Krebs-Ringer buffer of 1ml includes the 4- hydroxyethyl piperazineethanesulfonic acid of 25mM, the Portugal of 5.5mM Grape sugar and 2% (w/v) bovine serum albumin(BSA)) in culture 72 hours after, biopsy tissues simultaneously using hematoxylin and eosin progress Dyeing, is observed by 200 power microscopes (TS100, Nikon (Nicon) company) to compare the size of fat cell.
Experimental result compared with the control group, compares the big of fat cell when handling by concentration peptide complex It is small, as a result, to confirmed that the size of fat cell becomes smaller (Figure 10 a).Also, after being dyed, in order to measure fat cell Size and size that fat cell is measured using program is finally observed in peptide complex processing group, have obvious thin The reduction (Figure 10 b) for the adipose tissue inner cell size that after birth divides.
[2-6. observes the lipolytic factor of adipose tissue]
After the abdomen of fat inducing mouse acquisition adipose tissue, in 24 well culture plates, 100mg is put into each hole Adipose tissue after, culture medium (the Krebs-Ringer buffer of 1ml include 25mM 4- hydroxyethyl piperazineethanesulfonic acid, The glucose of 5.5mM and 2% (w/v) bovine serum albumin(BSA)) in cultivated.When being cultivated, to peptide complex into Row processing has handled the tumor necrosis factor-alpha of 100ng/ml, after culture 48 hours, it is thus identified that make as positive controls For the expression of the phosphokinase sensitive lipase (green fluorescence substance) of lipolytic factor.
Experimental result confirms the table of the phosphokinase sensitive lipase as the lipolytic factor in adipose tissue It reaches, as a result, when handling peptide complex, can confirm the phosphokinase sensitive lipase as lipolytic factor The increase (Figure 11) of expression.
[inhibition and lipolysis facilitation effect embodiment 3: are generated by the fat of experimental animal]
Weight loss and fat based on high fat diet, which generate, to be inhibited
Utilize the fat guidance model diet induced fertilizer induced by making normal C57BL/6 mouse absorb high fat diet Fat (DIO, Diets induced obesity) carries out anti-obesity effect experiment as positive controls drug and has used 5 μ g/ The tumor necrosis factor-alpha of ml.Control group is not carried out with the progress of general food with high fat diet, and experiment is absorbed 12 weeks High fat diet, and the reduction that peptide complex is handled, and positive controls are handled confirmed weight.
In 12 weeks, in 3 points~4 points of every afternoon, tumor necrosis factor-alpha and anti-obesity effect compound are forced into abdomen Chamber is injected 84 days, measures weight before first time is administered and dietary amount with one week for interval, determines weight and food later Object amount.Blood glucose after tail vein blood sampling, utilizes Roche vigor type blood glucose meter (Accu-Check after terminating administration experiment Active) (Roche) is measured, and cholesterol (Cholesterol) utilizes cholesterol also by the serum taken from tail vein Calculate kit (Cholesterol calculation Kit) (BioVision) Lai Jinhang analysis.According to color, fat Tissue is divided into white adipose, brown fat, and according to position, adipose tissue is divided into film fat between subcutaneous fat, stomach fat, intestines (interior fat) and epididymal adipose tissues.After dissection, each fat is extractd to be observed, in order to carry out histological examination, is incited somebody to action Lipopexia is planted in paraffin mass and is divided into 5 μm and has carried out bush after 10% neutral buffered formalin (Hematoxylin) it is dyed with Yihong (eosin).The phosphorylation degree of hormone-sensitive lipase as the lipolytic factor It is carried out by the fluorescent staining using anti-phosphokinase sensitive lipase antibody.After making tissue sample, pass through glycerol Glue installation medium (glycerine Jell mounting Media) is installed, and after covering glass cover, passes through microscope (Nikon Corporation, TS100) is observed, and is had taken tissue by being built in microscopical digital camera head.
Be confirmed as follows: the weight for absorbing general 12 weeks mouse of food rises to after 12 weeks from experiment initial stage 20.9g 28.74g, the weight for absorbing the mouse of high fat diet rise to 49.5g after 12 weeks from the 20.99g at initial stage.But with In high fat diet and use and the peptide complex group handled, 36.76g is risen to after 12 weeks from initial stage 21.1g, it is high with only intake The control group (235.8%) of fat diet is compared, and can confirm has high weight loss (174.2%) (table 2 and Figure 12).
[weight table 2: is measured later to Mice model of obesity processing peptide complex]
Also, in 12 weeks, pets that measurement experiment terminates, as a result, compared with the group for only absorbing high fat diet, In peptide complex processing group, the size of the body of observable mouse (figure similar with the size of normal mouse (general food) 13)。
The shooting of microcomputer layer scanning technology is carried out to the mouse for carrying out experiment in 12 weeks confirmed the rouge of entire body Fat distribution.Confirmation is distributed in the fat of entire body (in yellow), as a result, can be true compared with the control group for absorbing general food Recognize intake high fat diet control group mouse in, be distributed in entire body fat amount sharply increase, with it is high in fat Fat intake is handled together in the group of peptide complex, can confirm that the amount for being distributed in the fat of entire body sharply declines (Figure 14).
Dissection has shot the mouse of the microcomputer layer scanning technology of stomach and acquisition is distributed in the fat of entire body It organizes to observe the amount of adipose tissue.As a result, can confirm compared with the control group for absorbing general food and absorb high-fat drink The amount of fat in the mouse of the control group of food is more, is that high fat diet is handled together in the group of peptide complex, can confirm rouge The amount of fat sharply declines (Figure 15).
Fractionation of fatty simultaneously passes through the size of hematoxylin eosin staining (H&E) dyeing observation fat, as a result, can confirm and take the photograph The control group of high fat diet is taken to compare, in the processing group for absorbing peptide complex together with high fat diet, fatty size Become smaller (Figure 16 a).Fatty size is analyzed by program, as a result, is calculated as when by the fatty size of the control group of general food When 100%, absorb the control group of high fat diet fatty size be 127%, it is thus identified that fatty size becomes larger, and with it is high in fat Fat diet is absorbed together in the group of peptide complex, and fatty size is to reduce to 97% (Figure 16 b).
Fractionation of fatty simultaneously confirms that the phosphokinase sensibility as the lipolytic factor expressed in adipose tissue is fatty The result of the expression quantity of enzyme, it is thus identified that absorbed together with high fat diet in the processing group of peptide complex, phosphokinase sensibility The expression of lipase increases (Figure 17).
After completing experiment, the cholesterol amount in mouse blood is confirmed, as a result, absorb the cholesterol of the mouse of general food Amount is 2.52 μ g/ml, and the cholesterol amount for absorbing the control group of high fat diet is 3.5 μ g/ml, is absorbed together with high fat diet In the group of peptide complex, cholesterol amount is 2.86 μ g/ml.In peptide complex processing group, it can confirmed to reduce when obesity The numerical value (Figure 18) of the cholesterol risen.
The blood glucose numerical value in the mouse blood of experiment is completed in confirmation, as a result, absorbs the mouse of the control group of general food Blood glucose is 174mg/dL, and the blood glucose for absorbing the control group of high fat diet is 235mg/dL, thus can confirm the upper of blood glucose numerical value Rise, in the group for absorbing peptide complex together with high fat diet, blood glucose numerical value be 183mg/dL, thereby confirmed that reduce with Absorb the similar blood glucose numerical value of the control group of general food.
[embodiment 4: blood glucose adjustment]
[blood glucose adjustment effect]
C57BL/6 (normal mouse) ((strain) Samtako) and male C57BLKS/JLepr has been used in this zoopery (glycosuria model mice, db/db mouse) ((strain) is bought from central experimental animal), as anti-diabetic and/or anti-obesity effect Substance has used complexing agent, as positive controls drug, has used sitagliptin (sitagliptin).In the present embodiment In, for the polarity diabetes (single-dose) of normal mouse model and the model that there can be heredity diabetes, pass through Dextrose tolerance test (GTT, Glucose Tolerance Test) method as representative diabetes diagnosis inspection method Anti-diabetic and/or anti-obesity effect complexing agent are evaluated.The feeding environment condition of mouse is set as 22~24 DEG C, phase It is 50~30% to humidity, and raises four mouse in each rearing-box.150-300 Le gram is given at 8 points from 8 a.m. to afternoon The illumination of this (Lux), and turn on light 12 hours and turn off the light 12 hours daily.Feed used general diet (18% protein, 2018, Harlan Laboratories Inc, USA production) and absorb mouse freely, and before carrying out ITT experiment, make small Mouse is gone on a hunger strike 4 hours or more, and 12 hours before carrying out dextrose tolerance test start that mouse is made to go on a hunger strike.Executing, glucose is resistance to 1 hour before amount test, complexing agent is utilized respectively oral administration with disposable syringe to carry out pressure oral administration, in order to Dextrose tolerance test is carried out, when carrying out 0 time of experiment, makes the high fat diet of mouse intake 40 minutes.In free intake After high fat diet 40 minutes, in order to check respectively for the blood glucose in blood, with 0 minute, 30 minutes, 60 minutes, 90 minutes, It takes a blood sample from tail vein and determines blood glucose level using Roche vigor type blood glucose meter in 120 minutes and 180 minutes intervals.It is another Aspect has selected the current sitagliptin with for glycosuria therapeutic agent as positive controls drug, and with the administration of 100mg/kg Amount is administered.Complexing agent as anti-diabetic and/or the selection of anti-obesity effect rear portion substance presses the dosage of 100mg/kg Experimental group is divided, and each experimental group uses 4 public mouse.
Experimental result shows blood glucose because of the processing of peptide complex by the increased blood glucose numerical value of high fat diet and reduces effect Fruit.Cause in mouse model in diabetes, it is thus identified that the hyperglycemia of diabetes reduces (Figure 20 a, Figure 20 b).Also, it is high with intake The control group of fat diet is compared, and the drop of cholesterol amount is confirmed in the processing group for absorbing peptide complex together with high fat diet Low (referring to Figure 21).
Also, after so that the mouse for inducing DB/DB diabetes is maintained 16 hours empty stomaches, mouse is made to absorb 30 minutes diet Afterwards, and mouse is made to absorb peptide, and temporally determines blood glucose numerical value.
Experimental result observes the numerical value of hyperglycemia in the sequence 1, the group of the peptide of sequence 3 and sequence 5 of processing sequence table (Figure 22 a~Figure 22 c) is reduced in a manner of Time-Dependent.
[embodiment 5: insulin and insulin type promote like the expression of growth factor]
[insulin and insulin type promote like the expression of growth factor]
By 3 × 105The cell density of cells/well has planted 3T3-L1 (PECTORAL LIMB SKELETON) in 6 orifice plates.It is small in culture 24 When after, peptide is handled by concentration (μ of 10ng~1 g/ml), and has been cultivated 14 days in 37 DEG C of culture mediums.To cell dissolution Buffer is handled after ensuring dissolved matter, to quantify protein, using as the anti-pancreas islet of lipolytic factor Plain like growth factor 1 (IGF-1), insulin antibody (Santa Cruz Biotechnology, USA) divide to implement western blot It analyses and is observed.
Experimental result observes the peptide of the sequence 7 by sequence table, the table of para-insulin No.1 growth factor and insulin Up to increasing (Figure 23) in a manner of relying on concentration.
[effect observation embodiment 6: is reduced by the blood glucose of clinical trial]
[being reduced based on the blood glucose that complexing agent is taken]
It with fasting blood-glucose for 170mg/dL or more, and is within 45~65 years old object, simple clinical trial carries out fasting blood glycosyl Standard 30 minutes intake compound formulations and takes blood after the meal with 30,60,90,120,150,180 minutes intervals, and utilizes Roche Vigor type blood glucose meter determines blood glucose level.
Experimental result observes that the blood glucose based on compound formulation reduces (Figure 25 a~figure in every experimental subjects 25d)。
More than, specific part of the invention is described in detail, for those of ordinary skill in the art, explicitly It is that this detailed describe is only preferred embodiment, and the scope of the present invention is not intended to be limited thereto.Therefore, essential scope of the invention It is defined by the appended claimed range of invention and the technical solution being equal with it.
This specification further includes following content:
1. a kind of peptide, which is characterized in that by selected from the sequence 1 by sequence table into sequence 7 documented amino acid sequence One of group of composition amino acid sequence is formed.
2. a kind of peptide, there is anti-fat or anti-diabetic activity, which is characterized in that by selected from the sequence 1 by sequence table to One of the group of amino acid sequence composition of sequence 7 amino acid sequence is formed.
3. according to peptide described in embodiment 2, which is characterized in that above-mentioned peptide inhibits lipid to generate.
4. according to peptide described in embodiment 2, which is characterized in that above-mentioned peptide reduces peroxisome proliferator-activated receptor The expression of body γ, acetyl-CoA carboxylase or fatty specific fat acid binding protein 2.
5. according to peptide described in embodiment 2, which is characterized in that above-mentioned peptide increases lipolysis.
6. according to peptide described in embodiment 2, which is characterized in that above-mentioned peptide increases phosphokinase sensitive lipase, gland Thuja acid activated protein kinase α 1, icp gene identification -58 or the expression of fat triglyceride lipase.
7. according to peptide described in embodiment 2, which is characterized in that above-mentioned peptide reduces blood glucose.
8. a kind of peptide complex, there is anti-fat or anti-diabetic activity, characterized by comprising:
(a) peptide formed by the sequence of sequence table 1；
(b) peptide formed by the sequence of sequence table 2 or sequence 3: and
(c) peptide formed by the sequence of sequence table 6 or sequence 7.
9. according to peptide complex described in embodiment 8, which is characterized in that above-mentioned peptide complex reduces the big of fat cell It is small.
10. according to peptide complex described in embodiment 8, which is characterized in that above-mentioned peptide complex reduces the gallbladder in blood Sterol.
11. prevention or the treatment medicament composition of a kind of obesity, which is characterized in that comprising any in embodiment 2 to 7 Peptide described in is as effective component.
12. prevention or the treatment medicament composition of a kind of obesity, which is characterized in that comprising appointing in embodiment 8 to 10 Peptide complex described in one is as effective component.
13. prevention or the treatment medicament composition of a kind of diabetes, which is characterized in that comprising appointing in embodiment 2 to 7 Peptide described in one is as effective component.
14. prevention or the treatment medicament composition of a kind of diabetes, which is characterized in that comprising in embodiment 8 to 10 Described in any item peptide complexs are as effective component.
15. a kind of fat or diabetes preventions or treatment method, which is characterized in that including will be in embodiment 2 to 7 The step of pharmacy effective dose of described in any item peptides is administered into object.
16. a kind of fat or diabetes preventions or treatment method, which is characterized in that including will be in embodiment 8 to 10 The step of pharmacy effective dose of described in any item peptide complexs is administered into object.
Sequence table
<110> CAREGEN CO., LTD.
<120>have effects that anti-fat and anti-diabetic peptide and its purposes
<130> PP150058CN
<150> KR 15/0059648
<151> 2015-04-28
<160> 17
<170> KopatentIn 2.0
<210> 1
<211> 5
<212> PRT
<213>artificial sequence
<220>
<223>peptide 1
<400> 1
Leu Lys Thr Arg Asn
1 5
<210> 2
<211> 9
<212> PRT
<213>artificial sequence
<220>
<223>peptide 2
<400> 2
Lys Gly Ala Cys Thr Gly Trp Met Ala
1 5
<210> 3
<211> 9
<212> PRT
<213>artificial sequence
<220>
<223>peptide 3
<400> 3
Lys Gly Ala Ser Thr Gly Trp Met Ala
1 5
<210> 4
<211> 10
<212> PRT
<213>artificial sequence
<220>
<223>peptide 4
<400> 4
Ala Cys Tyr Leu Pro His Pro Trp Phe Cys
1 5 10
<210> 5
<211> 10
<212> PRT
<213>artificial sequence
<220>
<223>peptide 5
<400> 5
Ala Ser Tyr Leu Pro His Pro Trp Phe Ser
1 5 10
<210> 6
<211> 10
<212> PRT
<213>artificial sequence
<220>
<223>peptide 6
<400> 6
Cys Asp Leu Arg Arg Leu Glu Met Tyr Cys
1 5 10
<210> 7
<211> 10
<212> PRT
<213>artificial sequence
<220>
<223>peptide 7
<400> 7
Ser Asp Leu Arg Arg Leu Glu Met Tyr Ser
1 5 10
<210> 8
<211> 20
<212> DNA
<213>artificial sequence
<220>
<223> PPARγF
<400> 8
ttttcaaggg tgccagtttc 20
<210> 9
<211> 20
<212> DNA
<213>artificial sequence
<220>
<223> PPARγR
<400> 9
aatccttggc cctctgagat 20
<210> 10
<211> 24
<212> DNA
<213>artificial sequence
<220>
<223> ACC F
<400> 10
accttactgc catcccatgt gcta 24
<210> 11
<211> 24
<212> DNA
<213>artificial sequence
<220>
<223> ACC R
<400> 11
gtgcctgatg atcgcacgaa caaa 24
<210> 12
<211> 20
<212> DNA
<213>artificial sequence
<220>
<223> aP2 F
<400> 12
catcagcgta aatggggatt 20
<210> 13
<211> 20
<212> DNA
<213>artificial sequence
<220>
<223> aP2 R
<400> 13
acacattcca ccaccagctt 20
<210> 14
<211> 24
<212> DNA
<213>artificial sequence
<220>
<223> AMPK-a1 F
<400> 14
tgaccggaca taaagtggct gtga 24
<210> 15
<211> 24
<212> DNA
<213>artificial sequence
<220>
<223> AMPK-a1 R
<400> 15
tgatgatgtg agggtgcctg aaca 24
<210> 16
<211> 24
<212> DNA
<213>artificial sequence
<220>
<223> CGI58 F
<400> 16
tgtgcaggac tcttacttgg cagt 24
<210> 17
<211> 24
<212> DNA
<213>artificial sequence
<220>
<223> CGI58 R
<400> 17
gtttctttgg gcagaccggt ttct 24

Claims (6)

1. peptide is made of documented amino acid sequence in the sequence 3 of sequence table.
2. a kind of peptide complex has anti-fat or anti-diabetic activity, is made of following peptide:
(a) peptide being made of the amino acid sequence of the sequence of sequence table 3；
(b) peptide being made of the amino acid sequence of the sequence of sequence table 1 or sequence 2；And
(c) peptide being made of the amino acid sequence of the sequence of sequence table 6 or sequence 7.
3. prevention or the treatment medicament composition of a kind of obesity, it includes described in peptide described in claim 1 or claim 2 Peptide complex as effective component.
4. prevention or the treatment medicament composition of a kind of diabetes, it includes peptide described in claim 1 or claim 2 institutes The peptide complex stated is as effective component.
5. peptide described in claim 1 or peptide complex as claimed in claim 2 are in the fat drug of preparation prevention or treatment Purposes.
6. peptide described in claim 1 or peptide complex as claimed in claim 2 are in preparation prevention or the drug for the treatment of diabetes In purposes.
CN201910508329.1A 2015-04-28 2015-05-12 Peptide with anti-obesity and anti-diabetic effects and application thereof Active CN110172083B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020150059648A KR101669140B1 (en) 2015-04-28 2015-04-28 Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof
KR10-2015-0059648 2015-04-28
PCT/KR2015/004749 WO2016175362A1 (en) 2015-04-28 2015-05-12 Peptide having anti-diabetic and anti-obesity effects, and use thereof
CN201580004918.6A CN106459152B (en) 2015-04-28 2015-05-12 Have effects that anti-fat and anti-diabetic peptide and its purposes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580004918.6A Division CN106459152B (en) 2015-04-28 2015-05-12 Have effects that anti-fat and anti-diabetic peptide and its purposes

Publications (2)

Publication Number Publication Date
CN110172083A true CN110172083A (en) 2019-08-27
CN110172083B CN110172083B (en) 2022-12-30

Family

ID=57198486

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201580004918.6A Active CN106459152B (en) 2015-04-28 2015-05-12 Have effects that anti-fat and anti-diabetic peptide and its purposes
CN201910508327.2A Active CN110105432B (en) 2015-04-28 2015-05-12 Peptide with anti-obesity and anti-diabetic effects and application thereof
CN201910508329.1A Active CN110172083B (en) 2015-04-28 2015-05-12 Peptide with anti-obesity and anti-diabetic effects and application thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201580004918.6A Active CN106459152B (en) 2015-04-28 2015-05-12 Have effects that anti-fat and anti-diabetic peptide and its purposes
CN201910508327.2A Active CN110105432B (en) 2015-04-28 2015-05-12 Peptide with anti-obesity and anti-diabetic effects and application thereof

Country Status (22)

Country Link
US (4) US10351597B2 (en)
EP (4) EP3613758B1 (en)
JP (4) JP6606192B2 (en)
KR (1) KR101669140B1 (en)
CN (3) CN106459152B (en)
AU (4) AU2015393357B2 (en)
BR (4) BR122020019077B1 (en)
CA (4) CA3074836C (en)
CL (4) CL2017002718A1 (en)
CO (1) CO2017011998A2 (en)
EA (1) EA037799B1 (en)
ES (4) ES2895167T3 (en)
HK (1) HK1252251A1 (en)
IL (4) IL255263B (en)
MX (4) MX2017013847A (en)
MY (4) MY197887A (en)
NZ (4) NZ737077A (en)
PH (1) PH12017501983A1 (en)
SA (4) SA520420882B1 (en)
SG (4) SG10201913490WA (en)
WO (1) WO2016175362A1 (en)
ZA (1) ZA201708044B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101669140B1 (en) 2015-04-28 2016-10-26 (주)케어젠 Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof
KR101831888B1 (en) * 2016-04-15 2018-04-16 (주)케어젠 Peptides Having Activities for Anti-inflammation and Uses Thereof
KR101887576B1 (en) 2016-04-15 2018-08-13 (주)케어젠 Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof
KR101955511B1 (en) * 2016-08-17 2019-03-11 (주)진셀팜 Peptide having lipolysis promoting effect, and uses thereof
KR101887577B1 (en) * 2016-10-19 2018-09-10 (주)케어젠 Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof
KR102386705B1 (en) * 2016-11-07 2022-04-21 주식회사 삼양사 marker gene related with anti-adipogenic activity of allulose and use thereof
CN106749533B (en) * 2016-12-05 2020-08-18 华南理工大学 Anti-obesity heptadecapeptide LNNPSVCDCDCMMKAAR
CN106749524B (en) * 2016-12-05 2020-08-18 华南理工大学 Anti-obesity heptapeptide NPVWKRK
CN106518971B (en) * 2016-12-05 2019-12-10 华南理工大学 Anti-obesity decapeptide CANPHELPNK
CN106699846B (en) * 2016-12-05 2020-08-18 华南理工大学 Anti-obesity undecapeptide NALKCCHSCPA
JP2019034926A (en) * 2017-08-10 2019-03-07 小林製薬株式会社 Age-related obesity improver and lipolysis improver
KR101920047B1 (en) 2018-01-03 2018-11-19 (주)케어젠 Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof
KR102065150B1 (en) 2018-04-27 2020-01-10 (주)케어젠 A composition for preventing or treating obesity comprising isotretinoin-peptide conjugate as an effective ingredient
KR102171141B1 (en) * 2018-05-28 2020-10-28 중앙대학교 산학협력단 Composition for preventing, treating, or improving obesity comprising the peptides derived from LGI3 as the active ingredients
CN108676073B (en) * 2018-06-07 2021-10-26 华南理工大学 Anti-obesity decapeptide LLVVYPWTQR and application thereof
CN109081862A (en) * 2018-06-07 2018-12-25 华南理工大学 The anti-obesity tetrapeptide PQTR of one kind and its application
CN112010941B (en) * 2019-05-31 2022-08-16 华南理工大学 Blood sugar reducing heptapeptide
CN113248628B (en) * 2021-07-13 2021-10-22 南京市妇幼保健院 Milk-derived polypeptide derivative and application thereof in preparation of obesity prevention and treatment medicines, health-care products and food additives
KR20230046870A (en) * 2021-09-30 2023-04-06 (주)케어젠 Peptide Having Anti-Obesity and Uses Thereof
KR20230148629A (en) 2022-04-18 2023-10-25 (주)케어젠 Peptide Having Activity of Anti-Obesity and Anti-Diabetes and Uses Thereof
KR20230138832A (en) * 2022-03-24 2023-10-05 (주)케어젠 Peptide Complex Having Activity of Anti-Diabetes and Uses Thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060853A1 (en) * 2000-02-18 2001-08-23 Biovitrum Ab Transgenic animal model for obesity expressing foxc2
US20040002442A1 (en) * 2001-10-05 2004-01-01 Clark Pan Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
CN1980686A (en) * 2004-04-05 2007-06-13 安斯泰来制药有限公司 Antiobesity drug

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723699B1 (en) 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6693076B1 (en) * 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
US5516891A (en) 1992-06-16 1996-05-14 Kinerton, Ltd. Liquid phase synthesis of peptides and peptide derivatives
NZ255461A (en) * 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
CZ297338B6 (en) * 1996-03-01 2006-11-15 Novo Nordisk A/S Appetite-suppressing peptide, pharmaceutical composition in which the peptide is comprised and use thereof
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
US20020132767A1 (en) 2000-01-31 2002-09-19 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2001092523A2 (en) 2000-05-30 2001-12-06 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
CN100404673C (en) * 2001-02-19 2008-07-23 默克专利有限公司 Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
CA2388287A1 (en) * 2001-05-30 2002-11-30 Terry E. Graham Therapies for the prevention and treatment of diabetes and obesity
CN1886423A (en) 2002-01-18 2006-12-27 普罗特米克斯公司 Glycoisoforms of adiponectin and uses thereof
US20050143297A1 (en) 2003-05-26 2005-06-30 Jean-Pierre Rosat Method for the administration of ligands, agonists of ligands of the TNF family with reduced toxicity
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US8314061B2 (en) * 2006-01-09 2012-11-20 Children's Hospital Medical Center Adiponectin for treatment of various disorders
CN101395179B (en) * 2006-03-06 2013-01-02 凯尔杰有限公司 Peptides having activities of insulin like growth factor-1 and their uses
NZ572708A (en) * 2006-06-09 2011-11-25 Novartis Ag Stabilized insulin-like growth factor polypeptides
CN101091765A (en) * 2007-06-08 2007-12-26 余仁生国际有限公司 Medicinal comsns-and usage for preventing and treating diabets mellitus
KR101050429B1 (en) * 2009-03-18 2011-07-19 연세대학교 산학협력단 Composition for the prevention or treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphor as an active ingredient
WO2012088379A2 (en) * 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
EP2505641B1 (en) * 2011-04-01 2015-04-15 F. Hoffmann-La Roche AG T7 RNA polymerase variants with Cysteine-Serine substitutions
KR101363455B1 (en) * 2011-09-09 2014-02-21 (주)케어젠 Peptides Inhibiting the Activity of Matrix Metalloproteases and Use Thereof
KR20140027594A (en) * 2012-07-23 2014-03-07 씨지케이바이오 주식회사 Pharmaceutical composition having anti-diabetic and anti-obesity activties
JP6228215B2 (en) 2012-09-21 2017-11-08 ダウ グローバル テクノロジーズ エルエルシー Dye fixing agent and method
JP6387008B2 (en) * 2012-09-26 2018-09-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Insulin analog dimer
KR101510742B1 (en) * 2013-05-13 2015-04-10 (주)케어젠 Peptides for Inducing Mast Cell-Spepcific Apoptosis and Uses Thereof
EP3116526B1 (en) 2014-03-13 2019-10-23 Université Grenoble Alpes Pharmaceutical compositions comprising april for use the treatment of multiple sclerosis, autoimmune encephalitis, neuromyelitis optica, alzheimer disease or parkinson disease
KR101669140B1 (en) 2015-04-28 2016-10-26 (주)케어젠 Peptides having Anti-obesity and Anti-Diabetes Effects and Use Thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060853A1 (en) * 2000-02-18 2001-08-23 Biovitrum Ab Transgenic animal model for obesity expressing foxc2
US20040002442A1 (en) * 2001-10-05 2004-01-01 Clark Pan Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
CN1980686A (en) * 2004-04-05 2007-06-13 安斯泰来制药有限公司 Antiobesity drug

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
鞠现霞等: "胰高血糖素样肽1对脂肪细胞作用的研究进展", 《医学综述》 *

Also Published As

Publication number Publication date
EA201792365A1 (en) 2018-04-30
CL2017002718A1 (en) 2018-11-09
IL282513B (en) 2022-01-01
CA2984287A1 (en) 2016-11-03
BR122020019171B1 (en) 2023-11-07
CA3074800C (en) 2022-04-12
ES2831329T3 (en) 2021-06-08
IL255263B (en) 2022-02-01
SA520420882B1 (en) 2021-11-14
EP3290434B1 (en) 2020-08-19
WO2016175362A1 (en) 2016-11-03
AU2019203657A1 (en) 2019-06-13
AU2019203659A1 (en) 2019-06-13
CL2019002959A1 (en) 2020-02-21
NZ747392A (en) 2020-08-28
PH12017501983B1 (en) 2018-03-19
US20180118783A1 (en) 2018-05-03
ZA201708044B (en) 2022-09-28
IL282510A (en) 2021-06-30
CL2019002960A1 (en) 2020-02-21
US20190270774A1 (en) 2019-09-05
CA2984287C (en) 2021-01-19
AU2019203655A1 (en) 2019-06-13
MX2017013847A (en) 2018-06-15
US20190270773A1 (en) 2019-09-05
AU2019203655B2 (en) 2020-07-02
US10351597B2 (en) 2019-07-16
CA3074790A1 (en) 2016-11-03
CA3074836C (en) 2021-06-15
ES2894638T3 (en) 2022-02-15
CN110172083B (en) 2022-12-30
JP6813155B2 (en) 2021-01-13
EP3613760A1 (en) 2020-02-26
ES2893468T3 (en) 2022-02-09
MX2020012992A (en) 2022-10-13
CN110105432A (en) 2019-08-09
MX2020012994A (en) 2022-10-13
MY197887A (en) 2023-07-23
CL2019002958A1 (en) 2020-02-21
CA3074800A1 (en) 2016-11-03
CA3074790C (en) 2023-01-31
NZ747396A (en) 2020-10-30
SA517390237B1 (en) 2021-03-17
IL282510B (en) 2022-01-01
IL282514A (en) 2021-06-30
US10626145B2 (en) 2020-04-21
JP2020007372A (en) 2020-01-16
SG10201913489UA (en) 2020-02-27
AU2019203659B2 (en) 2020-07-02
AU2015393357A1 (en) 2017-11-30
JP2020007373A (en) 2020-01-16
CO2017011998A2 (en) 2018-02-09
EP3290434A1 (en) 2018-03-07
JP2018515471A (en) 2018-06-14
US10738081B2 (en) 2020-08-11
CN110105432B (en) 2022-12-27
SG10201913490WA (en) 2020-03-30
BR112017023199A2 (en) 2019-01-29
SG11201708847VA (en) 2017-11-29
SA520420881B1 (en) 2023-01-15
NZ737077A (en) 2019-05-31
PH12017501983A1 (en) 2018-03-19
MX2020012993A (en) 2022-10-13
AU2019203657B2 (en) 2020-07-02
EP3613759A1 (en) 2020-02-26
BR122020019077B1 (en) 2023-11-07
JP6813156B2 (en) 2021-01-13
MY197886A (en) 2023-07-23
EA037799B1 (en) 2021-05-21
US20190270772A1 (en) 2019-09-05
KR101669140B1 (en) 2016-10-26
IL255263A (en) 2018-04-30
AU2015393357B2 (en) 2019-05-16
ES2895167T3 (en) 2022-02-17
EP3613760B1 (en) 2021-07-28
MY192154A (en) 2022-08-02
IL282514B (en) 2022-01-01
MY197888A (en) 2023-07-23
JP2020007371A (en) 2020-01-16
EP3613759B1 (en) 2021-07-21
US11186611B2 (en) 2021-11-30
IL282513A (en) 2021-06-30
SG10201913487RA (en) 2020-02-27
SA520420880B1 (en) 2021-11-14
EP3613758B1 (en) 2021-07-21
JP6908085B2 (en) 2021-07-21
CA3074836A1 (en) 2016-11-03
JP6606192B2 (en) 2019-11-13
CN106459152A (en) 2017-02-22
HK1252251A1 (en) 2019-05-24
BR122020019095B1 (en) 2023-11-14
CN106459152B (en) 2019-06-28
BR112017023199B1 (en) 2023-11-07
NZ747390A (en) 2020-08-28
EP3290434A4 (en) 2018-08-15
EP3613758A1 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
CN106459152B (en) Have effects that anti-fat and anti-diabetic peptide and its purposes
JP6875516B2 (en) Peptides with anti-obesity and anti-diabetic effects, and their uses
CN108884131A (en) Has effects that anti-fat and peptide of anti-diabetic and application thereof
OA18548A (en) Peptide having anti-diabetic and anti-obesity effects and use thereof.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40007770

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant